— Know what they know.
Not Investment Advice

AIDX

20/20 Biolabs, Inc. Common Stock
1W: -20.2% 1M: -91.5% YTD: -91.5%
$2.02
+0.14 (+7.56%)
After Hours: $2.01 (-0.01, -0.60%)
NASDAQ · Healthcare · Medical - Devices · $9.9M · Alpha Radar Sell · Power 41
Smart Money Score
No convergence signal
Key Statistics
Market Cap$9.9M
52W Range1.852-50
Volume150,185
Avg Volume382,455
Beta-0.42
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOJonathan Cohen
Employees13
SectorHealthcare
IndustryMedical - Devices
IPO Date2023-06-15
15810 Gaither Road
Gaithersburg, MD 20877
US
(240) 453-6339
About 20/20 Biolabs, Inc. Common Stock

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
Cohen Jonathan M A-Award 352,936 $3.39 2026-03-03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms